HCA
ITCI

Harbor Capital Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Harbor Capital Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,921
Closed -$3M – 1565
2024
Q4 		$3M Buy
35,921
+947
+3% +$77.8K 0.13% 217
2024
Q3 		$2.56M Buy
34,974
+20,676
+145% +$1.55M 0.11% 251
2024
Q2 		$979K Buy
+14,298
New +$992K 0.07% 361
2023
Q3 		– Sell
-734
Closed -$46.5K – 662
2023
Q2 		$46.5K Buy
+734
New +$45.7K 0.01% 505

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Harbor Capital Advisors's ITCI Position: Q1 2025 in Review

Harbor Capital Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 35,921 shares — an estimated $3M sold.

Harbor Capital Advisors first reported a position in ITCI in Q2 2023 and held it in 4 quarters. The position peaked at $3M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Harbor Capital Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 35,921 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $3M.
  • Harbor Capital Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 4 quarters.
  • Harbor Capital Advisors's Intra-Cellular Therapies Inc. position peaked at $3M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Harbor Capital Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.